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Abstract
Background: We introduced a hypometabolic convergence index (HCI) to characterize in a single measurement the extent
to which a person’s fluorodeoxyglucose positron emission tomogram (FDG PET) corresponds to that in Alzheimer’s disease
(AD). Apolipoprotein E e4 (APOE e4) gene dose is associated with three levels of risk for late-onset AD. We explored the
association between gene dose and HCI in cognitively normal e4 homozygotes, heterozygotes, and non-carriers.
Methods: An algorithm was used to characterize and compare AD-related HCIs in cognitively normal individuals, including
36 e4 homozygotes, 46 heterozygotes, and 78 non-carriers.
Results: These three groups differed significantly in their HCIs (ANOVA, p= 0.004), and there was a significant association
between HCIs and gene dose (linear trend, p= 0.001).
Conclusions: The HCI is associated with three levels of genetic risk for late-onset AD. This supports the possibility of using a
single FDG PET measurement to help in the preclinical detection and tracking of AD.
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Introduction
Fluorodeoxyglucose (FDG) positron emission tomography
(PET) measurements of the cerebral metabolic rate for glucose
(CMRgl) provide a neuroimaging biomarker for the detection and
tracking of Alzheimer’s disease (AD) [1] and for distinguishing
Alzheimer’s disease (AD) from other dementias (e.g. frontotem-
poral dementia and dementia with Lewy bodies). This biomarker
is also efficacious in predicting future AD in persons with mild
cognitive impairment (MCI), as well as cognitively normal
individuals [2]. The potential value of preclinical identification
and tracking of AD is receiving increasing interest with the goal of
preventative intervention [3], and it is this which has sparked
recent research endeavors.
In that the apolipoprotein E (APOE) e4 allele is the major
genetic risk factor for late-onset Alzheimer’s disease (AD) [4] and
the APOE e4 gene dose (each additional copy of the e4 allele in a
person’s APOE genotype) is associated with a greater risk of AD
and a younger age at clinical onset [5], we previously used FDG
PET in 160 cognitively normal late-middle-aged APOE e4
homozygotes, heterozygotes, and noncarriers to characterize
associations between APOE e4 gene dose and lower CMRgl in
precuneus, posterior cingulate, parietal, temporal, and frontal
regions that are preferentially affected in patients with AD [6].
In this previous study, we were able to demonstrate that APOE
e4 gene dose was significantly correlated with hypometabolism in
postulated brain regions. Our methodology entailed use of
preselected regions of interest (ROI’s) with its inherent limitation
of inflated Type I error due to multiple regional comparisons. We
recently developed a voxel-based data analysis method that uses all
of the data in a person’s FDG positron emission brain tomogram
to produce a single measurement, an ‘‘AD-related hypometabolic
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convergence index (HCI)’’ [7]. This HCI characterizes the extent
to which the pattern and magnitude of a person’s brain FDG
alterations, relative to a normal control (NC) group, correspond to
the pattern and magnitude of the brain alterations in AD patients.
Because this methodology capitalizes on as much of the data in the
image as possible (rather than one or more preselected ROIs), it
overcomes the problem of inflated Type I error due to multiple
regional comparisons.
In this study, we used HCI’s for the same cognitively normal
late-middle-aged cohort with varying doses of APOE e4, along with
reference data from the AD Neuroimaging Initiative (ADNI) to
characterize these individuals, with the aim of determining if this
single FDG PET measurement could be used to characterize an
association between three levels of genetic risk of AD prior to the
onset of symptoms. Here we report that the HCI is associated with
three levels of genetic risk for late-onset AD.
Materials and Methods
Ethics Statement
All participants provided written informed consent, and agreed
not to be given any information about their APOE genotype. All
parts of the study were conducted in the United States with IRB
approval from The Banner Good Samaritan Hospital Institutional
Review Board Committee (Affiliated with: Banner Health).
Participants
This study capitalized on data originally acquired in 160
cognitively normal persons 47–68 years of age, who had a reported
first degree family history of Alzheimer’s dementia, and whose
FDG PET images were originally analyzed using a voxel-based
brain mapping algorithm, as described in a previous report [6].
Venous blood samples were drawn, and APOE genotypes were
Table 1. Subject characteristics, clinical ratings, and neuropsychological test scores.
Characteristic, rating, or test score e4Homozygotes e4Heterozygotes e4noncarriers P value
n= 36 n=46 n=78
Age, years 55.665.2 56.164.2 56.5 0.52
Gender (F/M) 23/13 30/16 49/29 0.96
Years of Education 15.862.5 16.062.6 15.862.3 0.99
MMSE score 29.760.6 29.960.4 29.660.7 0.38
HAM-D 2.563.3 1.761.9 3.964.7 0.08
Auditory verbal learning test scores
Total learning 47.668.0 48.569.4 50.2610.2 0.30
Short-term recall 9.462.5 10.462.5 10.363.4 0.07
Long-term recall 8.762.9 10.062.9 9.863.4 0.05
Complex figure test scores
Copy 34.961.5 33.962.9 34.361.9 0.10
Recall 18.466.1 19.066.6 17.666.1 0.60
Boston naming test 57.163.1 56.862.9 56.763.4 0.67
Wechsler Adult Intelligence Scale-Revised scores
Information 11.962.2 12.362.1 11.262.1 0.06
Digit span 11.362.2 11.662.9 11.362.7 0.81
Block design 11.962.7 12.262.7 11.962.5 0.83
Mental arithmetic 11.962.4 12.362.5 11.462.7 0.47
Similarities 12.462.2 12.562.0 11.861.9 0.28
Controlled oral word association test 44.4611.0 43.8611.5 47.7610.3 0.23
Wechsler memory Scale-Revised orientation subtest score 13.860.4 13.960.4 13.760.4 0.51
Values are means 6 SD with ranges in parentheses as appropriate. P values were calculated using the unpaired 2-tailed t-tests or 2-tailed Pearson x2 test, uncorrected
for multiple comparisons.
doi:10.1371/journal.pone.0067163.t001
Figure 1. Mean Hypometabolic Convergence Index (HCI) for
APOE e4 homozygotes (HM), heterozygotes (HT) and non-
carriers (NC) showed a positive association between the HCI
and the APOE e4 gene dose.
doi:10.1371/journal.pone.0067163.g001
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characterized with analysis by restriction fragment-length poly-
morphisms [8]. This cohort included 36 APOE e4 gene homozy-
gotes (HM), 46 e4 heterozygotes (HT) (all with e3/e4 genotype),
and 78 e4 noncarriers (NC) (60 with e3/e3 genotype and 18 with
e2/e3 genotype). The subjects denied any memory or other
cognitive skill impairment, and had scores of at least 28 on the
Folstein Mini Mental State Examination [9] and ,10 on the
Hamilton Depression Rating Scale (HAM-D) [10]. They did not
satisfy criteria for a current psychiatric disorder using a structured
psychiatric interview [11], and had a normal neurological
examination. The subjects were fully evaluated with clinical
ratings and a battery of neuropsychological tests, as well as
volumetric magnetic resonance imaging (MRI) and FDG brain
PET; and none of the participants had used psychoactive
medications for at least 2 weeks before their PET scan.
FDG PET
FDG PET was performed with 951/31 ECAT scanner
(Siemens, Knoxville, Tennessee) as previously described [6]. The
acquisition protocol included a 20-minute transmission scan, the
intravenous injection of 10 millicuries (mCi) (370 megabecquerels)
of 18F-fluorodeoxyglucose and a 60-minute dynamic sequence of
emission scans. The subjects had fasted for at least 4 hours prior to
the study, and lay quietly in a darkened room with eyes closed and
directed forward. FDG PET images were reconstructed using the
30–60 minute emission scans, filtered back projection, a Hanning
filter of 0.40 cycles per pixel and measured attenuation-correction,
resulting in 31 slices with in-plane resolution of about 8.5 mm full
width at half maximum (FWHM), an axial resolution of 5.0–
7.1 mm FWHM, a 3.375 mm slice thickness and a 10.4 cm axial
field of view. SPM5 (http://www.fil.ion.ucl.ac.uk/spm/) was used
to deform each individual’s FDG PET image into the coordinate
space of the Montreal Neurological Institute (MNI) template and
smoothed using a Gaussian filter with 15 mm FWHM.
Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Dataset
Data from a separate group of individuals participating in the
Alzheimer’s Disease Neuroimaging Initiative (ADNI) [12] study, a
longitudinal multisite study supported by the National Institutes of
Health, private pharmaceutical companies, and nonprofit organi-
zations, with approximately 50 medical center and university sites
across the United States and Canada (www.loni.ucla.edu/ADNI),
was used as an independent data set to establish a template for
defining patterns of regional hypometabolism associated with AD
for the HCI computations. Their baseline FDG PET scans were
downloaded from the ADNI Laboratory on Neuroimaging
(LONI) website (www.loni.ucla.edu/ADNI). This group included
68 subjects with probable AD and 78 elderly healthy controls
(HL). Individuals in the AD group had Mini-Mental State
Examination (MMSE) [9] scores of 20–26, had a Clinical
Dementia Rating (CDR) global score [13] of 0.5 or 1.0, and
met NINCDS/ADRDA criteria for probable AD [14]. HL had
MMSE scores of at least 24, a CDR global score of 0; and no
diagnosis of depression, Mild Cognitive Impairment (MCI), or
dementia. Additional inclusion and exclusion criteria, including
lists of approved medications and cognitive test measures for
inclusion, can be found on the ADNI website (www.loni.ucla.edu/
ADNI).
Each participating ADNI site acquired and reconstructed FDG-
PET data with the use of measured-attenuation correction and the
specified reconstruction algorithm for each scanner type according
to a standardized protocol (www.loni.ucla.edu/ADNI/Data/
ADNI_Data.shtml). All images were pre-processed by ADNI
PET Coordinating Center investigators at the University of
Michigan and uploaded to the LONI ADNI website. These
images were downloaded by investigators at Banner Alzheimer’s
Institute for additional pre-processing using SPM5 (http://www.
fil.ion.ucl.ac.uk/spm).
Computation of Hypometabolic Convergence Index (HCI)
FDG brain PET images from the 68 ADNI subjects with
probable AD were compared to those of 78 ADNI healthy controls
using a voxel-wise two-sample independent t-test implemented in
SPM5. In doing so, the image from each subject was normalized
for individual variations in whole brain measurements using
proportionate scaling. The resulting AD hypometabolic map (the
t-map of lower CMRgl in AD patients) was then transformed into
a z-score map of AD-like hypometabolism.
In addition to this AD hypometabolic map, the FDG-PET
images from 101 ADNI healthy controls (2 HMs, 24 HTs and 75
NCs of APOE e4) served as an independent normative database,
and were used to characterize the extent of regional CMRgl
reductions in each cognitively normal person with variable genetic
risk for LOAD in our Arizona cohort. Again, a two-sample t-test
was conducted comparing the image of a single individual in our
Arizona cohort to ones of the normative database (the single
subject his/herself as one group). Similarly, the T-score map was
generated for this subject and converted also to a z-score map as
previously described [7]. Thus, each member of our separate
cohort of cognitively normal individuals with varying doses of the
APOE e4 gene had his or her FDG PET comparative hypometa-
bolic map. This hypometabolic map and the above-noted AD-like
hypometabolic map were then used to calculate an HCI for this
subject; essentially as the sum of the product of z-scores from each
cerebral voxel [7].
Statistical Analysis
The three genetically distinct APOE e4 gene groups-HM, HT
and NC were compared in terms of their age, gender, educational
level, and performance on each of the neuropsychological
measures. A comparison of the HCI scores, using analysis of
variance (ANOVA), was performed, and Z-score voxel-wise
Figure 2. HCI z-score maps of AD-associated hypometabolism
in a APOE e4 homozygote (A), a APOE e4 heterozygote (B) and
a APOE e4 non-carrier (C) demonstrate differences in extent of
hypometabolism proportional to APOE e4 gene dose.
doi:10.1371/journal.pone.0067163.g002
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comparisons of AD-associated regions of hypometabolism were
produced for each diagnostic group. Two-sample t-tests (assuming
equal variances) were also performed on the HCI scores between
the groups as follows: NC and HT, NC and HM, and HM and
HT. Regression analysis was performed demonstrating the
association between HCI z-scores and APOE e4 gene dose, and
Pearson correlations were used to evaluate the relationship
between HCI index scores and cognitive measures.
Results
As shown in Table 1, The HM, HT, and NC groups did not
differ significantly in their age, sex, or educational level. There
were, likewise, no significant differences in neuropsychological test
performance with the exception of long term memory on the
AVLT [15], with trends in short term memory (all within age/
education adjusted normal limits). Significant differences were
seen in the group’s HCI’s (24.3864.84, 23.5863.59, and
21.8064.09, respectively for HM, HT and NC; ANOVA,
p=0.004), as shown in Figure 1. Additionally, there was a
significant association between HCI’s and the APOE e4 gene dose
(linear trend, p=0.001). Two sample t-tests performed on the HCI
scores between NC and HT, NC and HM, and HM and HT,
respectively, revealed significant differences between the HCI
scores of the NC and HT groups (p = 0.013) and the NC and HM
groups (p = 0.004), while no difference was found between the HM
and HT groups. The product image of the AD group hypome-
tabolism map (the z-score map) with the one from an individual is
helpful visually to see how these two are similar. Figure 2 shows
such product maps in a representative HM (row A), HT (row B)
and NC (row C) subject. There were no significant associations
between HCI scores and any cognitive measures.
Discussion
This study demonstrates an association between AD-related
HCIs and APOE e4 gene dose in a large group of previously
studied, cognitively normal, late-middle-aged e4 homozygotes,
heterozygotes, and non-carriers from the Arizona APOE cohort, and
indeed, significant differences among the three genetic groups. It
illustrates the possibility of characterizing the AD-related pattern
of cerebral hypometabolism in the preclinical detection of AD
using a summary index that is free from the Type I error
associated with multiple regional comparisons.
Whereas our previous publication focused on the HCI in the
context of distinguishing AD, MCI and normal controls, and
predicting MCI to AD conversion [7], our current study served as
a performance test of the HCI in cognitively normal individuals
and investigated its potential to distinguish these individuals with
different levels of genetic risk of AD. With the recently proposed
research criteria for preclinical AD, based on biomarker
measurements, there will be increasing interest in ways to
characterize AD biomarkers in a single sensitive measurement.
To the extent to which they are able to characterize the preclinical
stages of AD, these strategies may have potentially important roles
in research and clinical settings. Additional studies are needed to
determine the extent to which the HCI, alone or in combination
with other genetic or biomarker data, can help predict a person’s
subsequent clinical course, predict a differential response to
treatment, help to enrich prevention trials with those at highest
clinical risk, predict a differential response to future preclinical AD
treatments, or help in the evaluation of genetic and non-genetic
risk factors for AD.
We recognize a number of limitations to our study: These
include a significant overlap between the three group’s HCI’s,
suggesting relatively low sensitivity for the preclinical detection of
AD and the potential for refinement of this summary index
measurement. More information is also needed to determine the
extent to which the HCI, alone or in combination with other
genetic or biomarker measurements, is predictive of clinical course
or response to treatment; and, therefore, this summary index
measurement should not be used to predict an individual’s risk for
development of AD. Moreover, it is difficult based on the evidence
from FDG-PET alone to support, for example, a specific
pathological abnormality of preclinical AD without other data
showing Ab-amyloid pathology. In general, FDG-PET-revealed-
abnormalities could be related to a reduction in the activity or
density of the terminal neuronal fields or perisynaptic glial cells
that innervate these regions, a metabolic dysfunction, or a
combination of these factors [16]. We also note that the HCI
results from this study may not be directly compared to those in
our previous study on MCI and AD subjects as the normal
database used in this study is larger than that of the previous study.
However, to evaluate the reliability of the HCI measurement, we
have examined the differences in the HCI results using these two
overlapping, but different normal databases, and found that all
statistical significances observed are identical using either normal
database. Finally, our group has not yet applied this summary
index measurement for the tracking of longitudinal change in our
healthy subjects and in patients with AD or MCI. We are working
to extend this index to be applicable to longitudinal data and will
report the findings in future separate studies.
It is also important to acknowledge alternative approaches to
the characterization of AD in a single ROI or voxel-based index.
For example, Minoshima et al. [17] demonstrated that a ROI
encompassing the posterior cingulate cortex consistently indicated
significant FDG uptake (glucose metabolic) reduction in patients
with very early Alzheimer’s disease, and demonstrated utility
regarding prediction and analysis of actual patients.
Landau et al. [18] developed a single ‘‘metaROI’’ reflective of
glucose hypometabolism in specific brain regions established as
hypometabolic in previous FDG PET studies of AD and MCI, and
showed that radiotracer uptake in this composite ROI was a
sensitive measure of change in cognition and functional ability in
AD and MCI, and had value in predicting future cognitive decline
[19]. Herholz et al. [20], also using FDG PET data, derived an
AD summary index measure referred to as the ‘‘AD t-sum’’,
indicative of the severity of the hypometabolism in those brain
areas typically affected by AD, and demonstrated its utility in
monitoring the progression of MCI to AD [21]. In a recent
comparison study [22], HCI, metaROI and AD t-sum based
PALZ techniques performed comparably in differentiating AD,
MCI and healthy controls. Future studies are needed to compare
these indices and others in terms of the sensitivity of differentiating
cognitively normal individuals with different levels of AD risk.
The potential roles of brain imaging techniques depend not only
on the imaging modality used, but the way that the data are
analyzed. We anticipate that summary brain imaging measure-
ments like the HCI will continue to be developed, tested, and
applied in the preclinical study of AD.
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